Table 8.

Results of MTS assay in MCF‐7R cells following 72 h of treatment with fraction 8 and doxorubicin, either alone or in combination.

Treatments	Cell growth inhibition, %	Expected, %
FR 8: 5 µg/mL	5.0 ± 3.5
FR 8: 10 µg/mL	6.0 ± 4.2
Doxo: 2 µg/mL	10.5 ± 7.4
Doxo: 5 µg/mL	28.0 ± 0.0*
FR 8: 5 µg/mL + Doxo: 2 µg/mL	49.0 ± 0.7**	15.0 ± 3.0*, a
FR 8: 5 µg/mL + Doxo: 5 µg/mL	59.0 ± 0.7**	31.6 ± 1.0**, b
FR 8: 10 µg/mL + Doxo: 2 µg/mL	59.5 ± 0.3**	16.0 ± 3.9**, a
FR 8: 10 µg/mL + Doxo 5 µg/mL	60.0 ± 0.7**	32.0 ± 2.0**, a

Note: Data are expressed as the mean ± standard error of three independent experiments.

^** p < 0.01, versus the control

^* p < 0.05, versus the control.

^a p < 0.01, expected versus observed (one‐way ANOVA followed by Tukey's test).

^b p < 0.05, expected versus observed (one‐way ANOVA followed by Tukey's test).